solo para uso en investigación
Cat. No.: S2627
Estructura química
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| neuron cultures | Kinase assay | 2.5 μM | DMSO | induces α-tubulin hyperacetylation | ||
| neuron cultures | Function assay | ~10 μM | DMSO | protects against glutathione depletion-induced oxidative stress | ||
| 134/04 | Function assay | 7.5 µM | impairs myotube formation | |||
| C2C12 | Function assay | 7.5 µM | impairs myotube formation | |||
| HaCaT keratinocytes | Function assay | 10 μM | blocks arsenite from inducing Nrf2 protein translation | |||
| JURL-MK1 | Function assay | 10 μM | enhances cell adhesivity to fibronectin | |||
| CML-T1 | Function assay | 10 μM | enhances cell adhesivity to fibronectin | |||
| K562 | Function assay | 10 μM | enhances cell adhesivity to fibronectin | |||
| HL-60 | Function assay | 10 μM | enhances cell adhesivity to fibronectin | |||
| KMCH | Growth inhibitory assay | ~10 μM | decreases proliferation and anchorage-independent growth | |||
| THP-1 | Function assay | ~10 μM | inhibits TNF-α and IL-6 secretion | |||
| RAW 264.7 | Function assay | ~10 μM | attenuates NO production | |||
| HT3 | Function assay | ~5 μM | DMSO | induces the differential α-tubulin acetylation | ||
| SiHa | Function assay | ~5 μM | DMSO | induces the differential α-tubulin acetylation | ||
| CaSki | Function assay | ~5 μM | DMSO | induces the differential α-tubulin acetylation | ||
| SiHa | Function assay | ~5 μM | DMSO | inhibits Thapsigargin- or EGF-induced SOCE activation | ||
| CaSki | Function assay | ~5 μM | DMSO | inhibits Thapsigargin- or EGF-induced SOCE activation | ||
| MCF-7 | Growth inhibitory assay | 30 μM | DMSO | IC50=15 μM | ||
| MCF-7 | Function assay | 30 μM | DMSO | increases the microtubule acetylation level. | ||
| MCF-7 | Function assay | 30 μM | DMSO | stabilizes microtubules against cold-induced depolymerization | ||
| MCF-7 | Function assay | 15 μM | DMSO | stabilizes microtubules against nocodazole-induced disassembly | ||
| MCF-7 | Function assay | 30 μM | DMSO | alteres the assembly dynamics of interphase microtubules | ||
| MCF-7 | Function assay | 30 μM | DMSO | increases the binding of HDAC6 with interphase microtubules | ||
| PC12 | Function assay | ~3 μM | DMSO | up-regulates anti-oxidative gene expression related to transcription factor XBP1s | ||
| PC12 | Growth inhibitory assay | ~3 μM | DMSO | reverse H2O2-induced growth inhibition | ||
| HEK293T | Function assay | ~3 μM | DMSO | up-regulated XBP1s protein level | ||
| HEK293T | Function assay | ~3 μM | DMSO | delays XBP1s protein degradation via acetylation-mediated proteasomal degradation | ||
| Huh7 | Function assay | ~5 μM | DMSO | suppresses proliferation of hepatitis C virus replicon with EC50 = 0.3 μM | ||
| SKMEL21 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| SKMEL103 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| SKMEL28 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM164 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM1361a | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM1366 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM793 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM35 | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM983a | Growth inhibitory assay | ~500 nM | DMSO | inhibits cell proliferation | ||
| WM793 | Function assay | ~6 μM | DMSO | induce G1 arrest | ||
| WM164 | Function assay | ~6 μM | DMSO | induce G1 arrest | ||
| WM983a | Function assay | ~6 μM | DMSO | induce G1 arrest | ||
| WM164 | Function assay | ~3 μM | DMSO | augments expression of MHC class I and melanoma associated antigens | ||
| WM983a | Function assay | ~3 μM | DMSO | augments expression of MHC class I and melanoma associated antigens | ||
| IPC298 | Function assay | ~3 μM | DMSO | augments expression of MHC class I and melanoma associated antigens | ||
| SKMEL30 | Function assay | ~3 μM | DMSO | augments expression of MHC class I and melanoma associated antigens | ||
| TCa83 | Function assay | induces PTEN expression and membrane translocation | ||||
| 293T | Function assay | ~2 μg/ml | induces PTEN expression and membrane translocation | |||
| SACC-83 | Function assay | ~2 μg/ml | induces PTEN expression and membrane translocation | |||
| 293T | Function assay | ~2 μg/ml | induces PTEN acetylation at K163 | |||
| U-87 MG | Function assay | ~2 μg/ml | inhibits the migration and invasion | |||
| U-87 MG | Function assay | ~10 μM | inhibits AKT phosphorylation | |||
| U-87 MG | Growth inhibitory assay | ~10 μM | inhibits cell growth | |||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 371.86 | Fórmula | C20H21N3O2.HCl |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 1310693-92-5 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
|
In vitro |
DMSO
: 74 mg/mL
(198.99 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
HDAC6
(Cell-free assay) 15 nM
HDAC8
(Cell-free assay) 854 nM
|
|---|---|
| In vitro |
Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. In homocysteic acid (HCA) induced neurodegeneration assays, Tubastatin A displays dose-dependent protection against HCA-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM. At 100 ng/mL Tubastatin A increases Foxp3+ T-regulatory cells (Tregs) suppression of T cell proliferation in vitro. Tubastatin A treatment in C2C12 cells would lead to myotube formation impairment when alpha-tubulin is hyperacetylated early in the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyeperacetylated in myotubes. A recent study indicates that Tubastatin A treatment increases cell elasticity as revealed by atomic force microscopy (AFM) tests without exerting drastic changes to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L.
|
| Ensayo de quinasa |
Ensayos de inhibición enzimática
|
|
Los ensayos de inhibición enzimática son realizados por Reaction Biology Corporation, Malvern, PA, utilizando la plataforma Reaction Biology HDAC Spectrum. (www.reactionbiology.com) Los ensayos de HDAC1, 2, 4, 5, 6, 7, 8, 9, 10 y 11 utilizan proteína humana recombinante aislada; el complejo HDAC3/NcoR2 se utiliza para el ensayo de HDAC3. El sustrato para los ensayos de HDAC1, 2, 3, 6, 10 y 11 es un péptido fluorogénico de los residuos 379-382 de p53 (RHKKAc); el sustrato para HDAC8 es un dipéptido diacilo fluorogénico basado en los residuos 379-382 de p53 (RHKAcKAc). Se utiliza el sustrato Acetil-Lis (trifluoroacetil)-AMC para los ensayos de HDAC4, 5, 7 y 9. Tubastatin A se disuelve en DMSO y se prueba en modo IC50 de 10 dosis con una dilución en serie de 3 veces a partir de 30 μM. El compuesto de control Trichostatin A (TSA) se prueba en un IC50 de 10 dosis con una dilución en serie de 3 veces a partir de 5 μM. Los valores de IC50 se extraen mediante el ajuste de curvas de las pendientes dosis/respuesta.
|
|
| In vivo |
Daily treatment of Tubastatin A at 0.5mg/kg inhibits HDAC6 to promote Tregs suppressive activity in mouse models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection.
|
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Western blot | EGFR / p-AKT / AKT / p-ERK / ERK |
|
29665050 |
| Immunofluorescence | α-tubulin / Acetylated tubulin HDAC6 |
|
23798680 |